Price T Rowe Associates Inc. MD Increases Position in GSK PLC Sponsored ADR $GSK

Key Points

• Price T Rowe Associates Inc. MD has increased its stake in GSK PLC by 2.1%, now owning over 7.7 million shares valued at approximately $299.16 million as of its latest SEC filing.
• GSK's quarterly earnings report showed an EPS of $1.23, exceeding expectations and reflecting a 1.3% revenue increase year-over-year, with total revenue reaching $10.64 billion.
• GSK recently announced a quarterly dividend of $0.4206 per share, resulting in an annualized payout of $1.68 and a yield of 4.2%; its dividend payout ratio stands at 77.78%.

Price T Rowe Associates Inc. MD grew its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 2.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,722,314 shares of the pharmaceutical company's stock after purchasing an additional 155,392 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.37% of GSK worth $299,163,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Banco Bilbao Vizcaya Argentaria S.A. bought a new stake in shares of GSK in the 1st quarter valued at approximately $208,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of GSK during the 1st quarter worth approximately $3,663,000. Legacy Financial Advisors Inc. bought a new stake in shares of GSK during the 1st quarter worth approximately $274,000. Northern Trust Corp lifted its stake in shares of GSK by 5.1% during the 1st quarter. Northern Trust Corp now owns 2,165,884 shares of the pharmaceutical company's stock worth $83,906,000 after acquiring an additional 105,629 shares during the last quarter. Finally, Brooklyn Investment Group grew its holdings in shares of GSK by 2,126.3% in the first quarter. Brooklyn Investment Group now owns 13,625 shares of the pharmaceutical company's stock worth $528,000 after purchasing an additional 13,013 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GSK has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Stock Up 0.3%

Shares of GSK stock traded up $0.11 during mid-day trading on Wednesday, hitting $39.94. The stock had a trading volume of 3,757,879 shares, compared to its average volume of 5,114,532. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.26. The firm has a market capitalization of $81.35 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 1.72 and a beta of 0.51. The firm's 50-day moving average is $38.33 and its two-hundred day moving average is $38.16. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the prior year, the business earned $0.43 EPS. The business's revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. GSK's dividend payout ratio (DPR) is currently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.